Market Access China’s 4+7 drug procurement policy and its impact on the ph... It is estimated that China has around 10,000 pharmaceutical companies varying in size, strategy, and technology.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
